ABIVAX Société Anonyme (NASDAQ:ABVX) Short Interest Up 71.2% in November

ABIVAX Société Anonyme (NASDAQ:ABVX) was the target of a significant growth in short interest during the month of November. As of November 30th, there was short interest totalling 484,900 shares, a growth of 71.2% from the November 15th total of 283,200 shares. Approximately 0.9% of the company’s shares are sold short. Based on an average daily volume of 117,700 shares, the short-interest ratio is currently 4.1 days.

ABIVAX Société Anonyme Stock Down 7.1 %

Shares of ABVX stock opened at $7.11 on Friday. ABIVAX Société Anonyme has a 12 month low of $7.11 and a 12 month high of $17.02. The company has a 50 day simple moving average of $9.46 and a two-hundred day simple moving average of $11.34.

Analysts Set New Price Targets

Several equities analysts have recently commented on ABVX shares. Citizens Jmp raised shares of ABIVAX Société Anonyme to a “strong-buy” rating in a research note on Wednesday, December 4th. JMP Securities started coverage on shares of ABIVAX Société Anonyme in a report on Wednesday, December 4th. They set an “outperform” rating and a $33.00 target price for the company. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $38.67.

Hedge Funds Weigh In On ABIVAX Société Anonyme

Hedge funds have recently modified their holdings of the company. Point72 Asset Management L.P. lifted its holdings in ABIVAX Société Anonyme by 28.2% in the 3rd quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock worth $6,254,000 after purchasing an additional 119,300 shares in the last quarter. Walleye Capital LLC increased its stake in ABIVAX Société Anonyme by 45.8% during the third quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock worth $2,965,000 after acquiring an additional 80,807 shares during the last quarter. BNP Paribas Financial Markets increased its position in shares of ABIVAX Société Anonyme by 82.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock valued at $150,000 after purchasing an additional 5,900 shares during the last quarter. Finally, abrdn plc raised its stake in shares of ABIVAX Société Anonyme by 167.7% in the third quarter. abrdn plc now owns 316,431 shares of the company’s stock valued at $3,645,000 after acquiring an additional 198,225 shares during the period. 47.91% of the stock is currently owned by institutional investors.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.